Open AccessPopulation Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections
Author(s) -
Dan Li,
Philip E. Sabato,
Benjamin Guiastrennec,
Aziz Ouerdani,
HwaPing Feng,
Vincent Duval,
Carisa S De Anda,
P.S. Sears,
Margaret Z Chou,
Catherine Hardalo,
Natalya Broyde,
Matthew L. Rizk
Publication year - 2021
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00895-21
Subject(s) - medicine , pharmacokinetics , pharmacodynamics , population , skin infection , pharmacology , staphylococcus aureus , environmental health , biology , bacteria , genetics
Tedizolid phosphate is an oxazolidinone antibacterial agent approved for the treatment of Gram-positive acute bacterial skin and skin structure infections (ABSSSIs) in patients aged ≥12 years. To support the use of tedizolid phosphate in adolescents with ABSSSIs, a population pharmacokinetic (PK) model, developed using adult and pediatric data, was updated to include PK data from a phase 3 clinical trial (PN012) that evaluated the safety and efficacy of once-daily oral or intravenous 200-mg tedizolid phosphate treatment in adolescents (12 to <18 years) with ABSSSIs, along with emerging data from a phase 1 trial (PN013) in children (2 to <12 years).